Search

Your search keyword '"Jacoangeli, Francesca"' showing total 3 results
Start Over Author "Jacoangeli, Francesca" Topic hemodynamics
3 results on '"Jacoangeli, Francesca"'

1. Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan

Author

Dini, Frank L, Carluccio, Erberto, Bitto, Roberto, Ciccarelli, Michele, Correale, Michele, D'Agostino, Andreina, Dattilo, Giuseppe, Ferretti, Marco, Grelli, Arianna, Guida, Stefania, Jacoangeli, Francesca, Lupi, Laura, Luschi, Lorenzo, Masarone, Daniele, Mercurio, Valentina, Pacileo, Giuseppe, Pugliese, Nicola Riccardo, Rispoli, Antonella, Scelsi, Laura, Tocchetti, Carlo Gabriele, Brunetti, Natale Daniele, Palazzuoli, Alberto, Piepoli, Massimo, Nodari, Savina, Ambrosio, Giuseppe, Dini, Frank L, Carluccio, Erberto, Bitto, Roberto, Ciccarelli, Michele, Correale, Michele, D'Agostino, Andreina, Dattilo, Giuseppe, Ferretti, Marco, Grelli, Arianna, Guida, Stefania, Jacoangeli, Francesca, Lupi, Laura, Luschi, Lorenzo, Masarone, Daniele, Mercurio, Valentina, Pacileo, Giuseppe, Pugliese, Nicola Riccardo, Rispoli, Antonella, Scelsi, Laura, Tocchetti, Carlo Gabriele, Brunetti, Natale Daniele, Palazzuoli, Alberto, Piepoli, Massimo, Nodari, Savina, and Ambrosio, Giuseppe

Subjects
Aminobutyrates, Biphenyl Compounds, Hemodynamics, ejection fraction, haemodynamic, heart failure, prognosis, sacubitril/valsartan, Stroke Volume, Settore MED/11 - Malattie dell'Apparato Cardiovascolare, Humans, Valsartan, Cardiology and Cardiovascular Medicine, prognosi
Abstract

Aim: Echo-derived haemodynamic classification, based on forward-flow and left ventricular (LV) filling pressure (LVFP) correlates, has been proposed to phenotype patients with heart failure and reduced ejection fraction (HFrEF). To assess the prognostic relevance of baseline echocardiographically defined haemodynamic profile in ambulatory HFrEF patients before starting sacubitril/valsartan. Methods and results: In our multicentre, open-label study, HFrEF outpatients were classified into 4 groups according to the combination of forward flow (cardiac index; CI:< or ≥2.0 L/min/m2 ) and early transmitral Doppler velocity/early diastolic annular velocity ratio (E/e': ≥ or

Published
2022

2. Benefit from sacubitril/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: An echocardiographic study.

Author

Carluccio, Erberto, Dini, Frank L., Bitto, Roberto, Ciccarelli, Michele, Correale, Michele, D'Agostino, Andreina, Dattilo, Giuseppe, Ferretti, Marco, Grelli, Arianna, Guida, Stefania, Jacoangeli, Francesca, Lupi, Laura, Luschi, Lorenzo, Masarone, Daniele, Mercurio, Valentina, Pacileo, Giuseppe, Pugliese, Nicola Riccardo, Rispoli, Antonella, Scelsi, Laura, and Tocchetti, Carlo Gabriele

Subjects
*HEMODYNAMICS, *VENTRICULAR ejection fraction, *ENTRESTO, *HEART failure, *VALSARTAN
Abstract

Sacubitril/valsartan improves outcome in patients with heart failure (HF) with reduced left ventricular (LV) ejection fraction (EF, HFrEF). However, little is known about possible mechanisms underlying this favourable effect. To assess changes in echocardiographically-derived hemodynamic profiles induced by sacubitril/valsartan and their impact on outcome. In this multicenter, open-label study, 727 HFrEF outpatients underwent comprehensive echocardiography at baseline (before starting sacubitril/valsartan) and after 12 months. Estimated LV filling pressure (E/e') and cardiac index (CI, l/min/m2) were combined to determine 4 hemodynamic profiles: profile-A (normal-flow/normal-pressure); profile-B (low-flow/normal-pressure); profile-C: (normal-flow/high-pressure); profile-D: (low-flow/high-pressure). Changes among categories were recorded, and their associations with rates of the composite of death/HF-hospitalization were assessed by multivariable Cox analysis. At baseline, 29% had profile-A, 15% had profile-B, 32% profile-C, and 24% profile-D. After 12 months, the hemodynamic profile improved in 53% of patients (all profile-A achievers, or profile-D patients achieving either C or B profile), while it remained unchanged in 39% patients and worsened in 9%. Prevalence of improved profile progressively increased with increasing dose of sacubitril/valsartan (P < 0.0001). After the second echocardiography, patients were followed up 12.6 ± 7.6 months: event-rate was lower in patients with improved profile (12.3%, 95%CI: 9.4–16.1) compared to patients in whom hemodynamic profile remained unchanged (29.9%, 24.0–37.3) or worsened (31.2%, 20.7–46.9, P < 0.0001). Improved hemodynamic profile was associated with favourable outcome independent of LVEF and other covariates (HR 0.65, 95%CI: 0.45–0.95, P < 0.05). In HFrEF patients, the beneficial prognostic effects of sacubitril/valsartan are associated with improvement in hemodynamic conditions. • Sacubitril/valsartan (S/V) improves outcome in HFrEF outpatients. • S/V improves non-invasive assessment of cardiac output and LV filling pressure. • Long-term risk of death/HF-hospitalization is reduced after this hemodynamic improvement. • Prognostic benefit of hemodynamic improvement is independent on LVEF improvement. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

3. Benefit from sacubitril/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: An echocardiographic study

Author

Erberto, Carluccio, Dini, Frank L., Bitto, Roberto, Michele, Ciccarelli, Michele, Correale, Andreina, D’Agostino, Dattilo, Giuseppe, Marco, Ferretti, Arianna, Grelli, Stefania, Guida, Francesca, Jacoangeli, Laura, Lupi, Lorenzo, Luschi, Daniele, Masarone, Valentina, Mercurio, Giuseppe, Pacileo, Nicola Riccardo Pugliese, Antonella, Rispoli, Laura, Scelsi, Carlo Gabriele Tocchetti, Natale Daniele Brunetti, Alberto, Palazzuoli, Massimo, Piepoli, Savina, Nodari, Giuseppe, Ambrosio, Working Group on Heart Failure of the Italian Society of, Cardiology., Carluccio, Erberto, Dini, Frank L., Bitto, Roberto, Ciccarelli, Michele, Correale, Michele, D'Agostino, Andreina, Dattilo, Giuseppe, Ferretti, Marco, Grelli, Arianna, Guida, Stefania, Jacoangeli, Francesca, Lupi, Laura, Luschi, Lorenzo, Masarone, Daniele, Mercurio, Valentina, Pacileo, Giuseppe, Pugliese, Nicola Riccardo, Rispoli, Antonella, Scelsi, Laura, Tocchetti, Carlo Gabriele, Brunetti, Natale Daniele, Palazzuoli, Alberto, Piepoli, Massimo, Nodari, Savina, and Ambrosio, Giuseppe

Subjects
Ejection fraction, Heart failure, Hemodynamic, Prognosis, Sacubitril/valsartan, Aminobutyrates, Biphenyl Compounds, Hemodynamics, Tetrazoles, Heart failure, Ejection fraction, Hemodynamic, Prognosis, Sacubitril/valsartan, Stroke Volume, Angiotensin Receptor Antagonists, Drug Combinations, Treatment Outcome, Echocardiography, Humans, Valsartan, Cardiology and Cardiovascular Medicine
Abstract

Sacubitril/valsartan improves outcome in patients with heart failure (HF) with reduced left ventricular (LV) ejection fraction (EF, HFrEF). However, little is known about possible mechanisms underlying this favourable effect.To assess changes in echocardiographically-derived hemodynamic profiles induced by sacubitril/valsartan and their impact on outcome.In this multicenter, open-label study, 727 HFrEF outpatients underwent comprehensive echocardiography at baseline (before starting sacubitril/valsartan) and after 12 months. Estimated LV filling pressure (E/e') and cardiac index (CI, l/min/mAt baseline, 29% had profile-A, 15% had profile-B, 32% profile-C, and 24% profile-D. After 12 months, the hemodynamic profile improved in 53% of patients (all profile-A achievers, or profile-D patients achieving either C or B profile), while it remained unchanged in 39% patients and worsened in 9%. Prevalence of improved profile progressively increased with increasing dose of sacubitril/valsartan (P 0.0001). After the second echocardiography, patients were followed up 12.6 ± 7.6 months: event-rate was lower in patients with improved profile (12.3%, 95%CI: 9.4-16.1) compared to patients in whom hemodynamic profile remained unchanged (29.9%, 24.0-37.3) or worsened (31.2%, 20.7-46.9, P 0.0001). Improved hemodynamic profile was associated with favourable outcome independent of LVEF and other covariates (HR 0.65, 95%CI: 0.45-0.95, P 0.05).In HFrEF patients, the beneficial prognostic effects of sacubitril/valsartan are associated with improvement in hemodynamic conditions.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results